Reported Earlier, Longeveron Shares Long-term Data On Transplant-free Survival with Lomecel-B In Hypoplastic Left Heart Syndrome (HLHS) At the 51st Annual Meeting CHSS
Portfolio Pulse from Benzinga Newsdesk
Longeveron presented long-term data on Lomecel-B for Hypoplastic Left Heart Syndrome (HLHS) at the 51st Annual Meeting CHSS. The study showed 100% transplant-free survival after 5 years, compared to 83% in a previous trial. The ongoing ELPIS II trial continues to evaluate Lomecel-B's efficacy.
October 28, 2024 | 6:54 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Longeveron's Lomecel-B shows promising results in HLHS treatment with 100% transplant-free survival over 5 years. This could enhance the company's reputation and stock value as ELPIS II trial progresses.
The 100% transplant-free survival rate in the ELPIS I study is a significant improvement over previous data, suggesting Lomecel-B's potential as a breakthrough treatment. This positive outcome is likely to boost investor confidence and positively impact LGVN's stock price, especially as the ELPIS II trial continues.
CONFIDENCE 95
IMPORTANCE 85
RELEVANCE 90